Sionna Therapeutics, Inc.

Aardvark Therapeutics’ drug candidates are designed to reduce hunger, but the company worked up enough of an appetite among investors to support the company’s initial public offering – the fifth bioph

Sionna Therapeutics has multiple drug candidates in the clinic and an ambition to improve cystic fibrosis treatment beyond what Vertex Therapeutics has achieved with its blockbuster portfolio of cysti

Biotech IPOs staged a moderate recovery in 2024 but a muted end to the year showed how fragile the market remains for companies looking to launch. Full year data shows 26 companies debuted on US excha

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sionna Gets CF Compounds AbbVie License